Cannabis use is the most commonly used drug in the USA with approximately 22.2 million users each month [1]. Research on chronic regular use of the drug has revealed numerous complications including erectile dysfunction, infertility, hearing, and visual disorders, along with psychosis and schizophrenia [2]. The first documented case of cannabis-induced pancreatitis was in 2004 and since then there have been 13 cases of cannabis-induced pancreatitis reported. However, the true incidence is likely under-estimated as patients may be reluctant to divulge in illicit drug use due to the illegal status of cannabis in many states. Therefore, a urine toxicology screening test is essential in making the diagnosis in addition to ruling out other more common causes of pancreatitis.

Unfortunately, the pathophysiology of marijuana-induced pancreatitis is poorly understood, and studies are still underway to determine the exact mechanism. The active component of marijuana is tetrahydrocannabinol (THC) which acts on cannabinoid receptors CB1 and CB2. CB1 receptor is found in the central nervous system, peripheral endothelial cells, and smooth muscle cells while CB2 receptors are closely linked to immune tissues such as the spleen and macrophages [3,4]. However, both CB1 and CB2 receptors are found in the islet of Langerhan cells of the pancreas. Studies have shown that the administration of the cannabinoid receptor agonist anandamide in mice with cerulein-induced pancreatitis increases the severity of pancreatitis Administration of anandamide increased pancreatic tissue damage and increased serum concentration of proinflammatory interleukin 1B and serum activity of pancreatic enzymes. The opposite effect was seen with administration of AM-251, a selective CB1 receptor antagonist [3,4].

Given the increased availability of cannabis for recreational and medicinal purposes in managing chronic pain, patients along with practitioners should be aware of the association between marijuana and pancreatitis. As demonstrated in our case presentation, our patient underwent a battery of tests including MRI, ultrasound, blood work, and endoscopy to determine patient’s etiology of pancreatitis and abdominal pain. However, an extensive history including social history and a urine toxicology screening may have prevented these unnecessary tests for the patient. Not only would this have expedited our patient's care, but also it would have significant cost savings to do a urine drug screen compared to the numerous expensive exams that our patient had to endure.

With acute pancreatitis being one of the leading cause of hospitalization among gastrointestinal disorders in the USA in combination with the legalization of medical and recreational use of cannabis in many states, it is very important to consider cannabis use as a cause of pancreatitis [5]. Often times, 20% of cases of pancreatitis cases are labeled as idiopathic [6] as a complete workup by fails to reveal a cause of the disease however, with the rising prevalence of cannabis use and its role as an overlooked cause of pancreatitis, health-care providers should include cannabis use as a possible differential for acute pancreatitis and should highly consider obtaining a urine toxicology screening test especially in young patients where the etiology of pancreatitis remains unknown.